Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center
1677
mi
from 98109
Dallas, TX
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center
1677
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
University of TX Medical Branch
mi
from 98109
Galveston, TX
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
University of TX Medical Branch
mi
from 98109
Galveston, TX
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
UT Health Science Center - San Antonio
1780
mi
from 98109
San Antonio, TX
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
UT Health Science Center - San Antonio
1780
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Baptist Medical Center
2294
mi
from 98109
Greensboro, NC
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Baptist Medical Center
2294
mi
from 98109
Greensboro, NC
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Wayne State University
1931
mi
from 98109
Detroit, MI
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Wayne State University
1931
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
1931
mi
from 98109
Detroit, MI
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
1931
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
University of Florida Department of Aging and Geriatrics
2452
mi
from 98109
Gainesville, FL
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
University of Florida Department of Aging and Geriatrics
2452
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Phalen Village Clinic
1401
mi
from 98109
Saint Paul, MN
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Phalen Village Clinic
1401
mi
from 98109
Saint Paul, MN
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Howard University
2322
mi
from 98109
Washington,
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Howard University
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting
Status: Enrolling
Updated:  12/31/1969
Cognitive-Behavioral Therapy and Behavioral Medicine Programs, Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting
Status: Enrolling
Updated: 12/31/1969
Cognitive-Behavioral Therapy and Behavioral Medicine Programs, Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Motivational Interviews for Depression in Primary Care
Motivational Interviews Adapted to Improve Depression Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Denver Health and Hospital Authority
1019
mi
from 98109
Denver, CO
Motivational Interviews for Depression in Primary Care
Motivational Interviews Adapted to Improve Depression Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Denver Health and Hospital Authority
1019
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
2079
mi
from 98109
Birmingham, AL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10358
980
mi
from 98109
Anaheim, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10358
980
mi
from 98109
Anaheim, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10390
977
mi
from 98109
Cerritos, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10390
977
mi
from 98109
Cerritos, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10740
985
mi
from 98109
Garden Grove, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10740
985
mi
from 98109
Garden Grove, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 177
1081
mi
from 98109
Imperial, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 177
1081
mi
from 98109
Imperial, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10665
1030
mi
from 98109
Oceanside, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10665
1030
mi
from 98109
Oceanside, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 14815
968
mi
from 98109
Pico Rivera, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 14815
968
mi
from 98109
Pico Rivera, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1065
mi
from 98109
San Diego, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 14779
926
mi
from 98109
Santa Ana, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 14779
926
mi
from 98109
Santa Ana, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 295
mi
from 98109
Sherman Oaks, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 295
mi
from 98109
Sherman Oaks, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 122
mi
from 98109
Temecula, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 122
mi
from 98109
Temecula, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12299
2453
mi
from 98109
Gainesville, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12299
2453
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 606
mi
from 98109
Jacksonville Beach, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 606
mi
from 98109
Jacksonville Beach, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 021
2452
mi
from 98109
Jacksonville, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 021
2452
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 127
mi
from 98109
Lauderhill, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 127
mi
from 98109
Lauderhill, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10664
2726
mi
from 98109
North Miami, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10664
2726
mi
from 98109
North Miami, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
2527
mi
from 98109
Tampa, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 096
2178
mi
from 98109
Atlanta, GA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 096
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 204
mi
from 98109
Smyrna, GA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 204
mi
from 98109
Smyrna, GA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 107
mi
from 98109
Naperville, IL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 107
mi
from 98109
Naperville, IL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 219
mi
from 98109
Oakbrook Terrace, IL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 219
mi
from 98109
Oakbrook Terrace, IL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 195
mi
from 98109
Park Ridge, IL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 195
mi
from 98109
Park Ridge, IL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 600
mi
from 98109
Lafayette, IN
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 600
mi
from 98109
Lafayette, IN
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 14747
2320
mi
from 98109
Pikesville, MD
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 14747
2320
mi
from 98109
Pikesville, MD
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 603
mi
from 98109
Watertown, MA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 603
mi
from 98109
Watertown, MA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 290
mi
from 98109
Flowood, MS
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 290
mi
from 98109
Flowood, MS
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10552
1720
mi
from 98109
Saint Louis, MO
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10552
1720
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 103
mi
from 98109
Mount Laurel, NJ
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 103
mi
from 98109
Mount Laurel, NJ
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1184
mi
from 98109
Albuquerque, NM
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10187
2407
mi
from 98109
Brooklyn, NY
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10187
2407
mi
from 98109
Brooklyn, NY
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1355
2401
mi
from 98109
New York, NY
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1355
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10112
2161
mi
from 98109
Rochester, NY
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10112
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 110
2399
mi
from 98109
Staten Island, NY
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 110
2399
mi
from 98109
Staten Island, NY
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
2361
mi
from 98109
Raleigh, NC
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
2361
mi
from 98109
Raleigh, NC
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 190
mi
from 98109
Beachwood, OH
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 190
mi
from 98109
Beachwood, OH
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10522
2057
mi
from 98109
Canton, OH
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10522
2057
mi
from 98109
Canton, OH
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1967
mi
from 98109
Cincinnati, OH
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1313
1959
mi
from 98109
Dayton, OH
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1313
1959
mi
from 98109
Dayton, OH
Click here to add this to my saved trials